Skip to main content

Table 4 Crude and adjusted Cox-proportional hazard regression output for the predictors of opportunistic infections among HIV -infected paediatrics at JMC, April 10–May 10, 2017

From: Abacavir versus Zidovudine-based regimens for treatment of HIV-infected children in resource limited settings: a retrospective cohort study

VariablesOIsCHR [95%CI]p-valueAHR[95%CI]p-value
YesNo    
SexMale30 (30.668 (69.4)1   
Female28 (34.6)53 (65.4)0.94 [0.55–1.59]0.810  
Age: Median IQR7 (4–9)58 (32.4)121 (67.6)1.00 [0.91–1.09]0.995  
Base-line body mass indexBelow 5th centile53 (37.9)87 (62.1)3.63 [1.45–9.10]0.006  
Above 5thcentile5 (12.8)34 (87.2)1   
Weight for height< 70%15 (41.7)21 (58.3)1.34 [0.74–2.44]0.332  
70–85%2 (14.3)12 (85.7)0.42 [0.10–1.73]0.229  
> 85%41 (31.8)88 (68.2)1   
In care of the childMother7 (29.2)17 (70.8)1   
Other51 (32.9)104 (67.1)0.66 [0.28–1.54]0.332  
Maternal statusLive47 (32.2)99 (67.8)1   
Dead11 (33.3)22 (66.7)1.17 [0.59–2.32]0.654  
Maternal sero-statusUnknown6 (33.3)12 (66.7)0.71 [0.28–1.81]0.476  
Negative52 (32.3)109 (67.7)1   
Paternal statusLive43 (32.6)89 (67.4)1   
Dead15 (31.9)32 (68.1)0.88 [0.48–1.62]0.694  
ResidenceUrban49 (36.6)85 (63.4)1   
Rural9 (20)36 (80)1.81 [0.885–3.69]0.104  
ART groupABC27 (31)60 (69)1.05 [0.62–1.76]0.885  
AZT29 (31.5)63 (68.5)1   
CD4 counta162 (117–221)58 (32.4)121 (67.6)0.98 [0.97–0.98]< 0.0010.99 [0.98–0.99]< 0.001
Baseline Viral load< 1000copes/ml36 (24.7)110 (75.3)1 1 
>1000copes/ml19 (65.5)10 (34.5)2.87 [1.62–5.10]< 0.0011.72 [0.91–3.24]0.094
WHO StageStage I5 (45.5)6 (54.5)1   
Stage II15 (23.4)49 (76.6)0.39 [0.14–1.06]0.066  
Stage III31 (35.6)56 (64.4)0.59 [0.23–1.52]0.276  
Stage IV7 (41.2)10 (58.8)0.80 [0.25–2.53]0.707  
Baseline nutritional statusNormal4 (3.9)98 (96.1)1 1 
SAM54 (70.1)23 (29.9)28.37 [10.23–78.73]< 0.00115.92 [5.34–47.50]< 0.001
TB treatmentNo46 (27.7)120 (72.3)1 1 
Yes12 (92.3)1 (7.7)8.58 [4.33–17.01]< 0.0012.93 [1.39–6.17]0.005
  1. CHR Crude hazard ratio, AHR Adjusted hazard ratio, ABC Abacavir, ART antiretroviral therapy, AZT Azidothymidine, WHO world health organization, TB Tuberculosis
  2. aBaseline CD4 count expressed in median and interquartile range (IQR)